USRE39480E1 - Chromium/biotin treatment of type II diabetes - Google Patents
Chromium/biotin treatment of type II diabetes Download PDFInfo
- Publication number
- USRE39480E1 USRE39480E1 US09/912,472 US91247201A USRE39480E US RE39480 E1 USRE39480 E1 US RE39480E1 US 91247201 A US91247201 A US 91247201A US RE39480 E USRE39480 E US RE39480E
- Authority
- US
- United States
- Prior art keywords
- biotin
- chromic tripicolinate
- chromium
- micrograms
- per day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Definitions
- the present invention relates to the treatment of adult-onset non-insulin dependent (Type II) diabetes. More specifically, the invention relates to the treatment of Type II diabetes by administering chromic picolinate and biotin.
- Diabetes mellitus is known to affect at least 10 million Americans, and millions more may unknowingly have the disease.
- Type II non-insulin dependent or adult-onset (as opposed to juvenile diabetes or Type I)
- the pancreas often continues to secrete normal amounts of insulin.
- this insulin is ineffective in preventing the symptoms of diabetes which include hyperglycemia, impaired carbohydrate metabolism, glycosuria and decreased insulin sensitivity. These symptoms, if left untreated, often lead to severe complications.
- the biguanides e.g. metformin
- the sulfonylureas e.g. tolbutamide and glyburide, lower plasma glucose primarily by stimulating insulin secretion, by enhancing insulin effects in some target tissues and by inhibiting hepatic glucose synthesis.
- U.S. Pat. No. 4,315,927 discloses that when selected essential metals are administered to mammals as exogenously synthesized coordination complexes of picolinic acid, they are directly available for absorption without competition from other metals. These complexes are safe, inexpensive, biocompatible and easy to produce.
- U.S. Pat. No. 5,087,623 describes the administration of chromic tripicolinate for the treatment of Type II diabetes in doses which provide between 50 and 500 ⁇ g of chromium.
- the U.S. Recommended Daily Allowance for chromium is 50-200 ⁇ g.
- PCT/US96/06493 discloses the administration of high (“supranutritional”) doses of chromium (1,000 to 10,000 ⁇ g/day) to individuals with Type II diabetes. Individuals who received 1,000 ⁇ g chromium per day as chromic tripicolinate exhibited a 30% decrease in glycosylated hemoglobin and a similar reduction in fasting and postprandial glucose levels.
- Biotin is the prosthetic group for a number of carboxylation reactions, the most notable being pyruvate carboxylase which is involved in gluconeogenesis and replenishment of the citric acid cycle, and acetyl CoA carboxylase which plays a role in fatty acid biosynthesis.
- the safe and adequate recommended daily intake of biotin is 100-300 ⁇ g, although no side effects or toxicities were noted in previous clinical studies with oral biotin intakes of up to 200 mg daily (Mock et al, in Present Knowledge in Nutrition, seventh edition, Ziegler, E. et al., eds., ILSI Press, Washington, D.C., 1996, pp. 220-235).
- the present invention addresses this need by providing a safe, inexpensive, drug-free therapeutic agent.
- One embodiment of the present invention is a method for reducing hyperglycemia and stabilizing the level of serum glucose comprising administering to an individual in need thereof between about 50 to 1,000 micrograms per day of chromium as synthetic chromic tripicolinate in combination with between about 25 ⁇ g and 200 mg per day of biotin, the amounts of chromic tripicolinate and biotin being selected together to provide a greater than additive effect.
- the amount of chromium administered as synthetic chromic tripicolinate is between 500 and 1,000 micrograms per day.
- the amount of biotin administered per day is between about 1 mg and 100 mg.
- the chromic tripicolinate is in a pharmaceutically acceptable carrier.
- the biotin is in a pharmaceutically acceptable carrier.
- the biotin is orally administered.
- the chromic tripicolinate is orally administered.
- the chromic tripicolinate is parenterally administered.
- the biotin is parenterally administered.
- the present invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising chromium as synthetic chromic tripicolinate and biotin, wherein the ratio of chromium to biotin is between about 2:1 and 1:200 (w/w), the amounts of chromic tripicolinate and biotin being selected together to provide a greater than additive effect.
- the present invention includes the discovery that doses of chromium from the highest RDA amount up to five times this amount, administered in the form of chromic picolinate, combined with either low or high doses of biotin, promote significant reduction in blood glucose levels and stabilize blood glucose levels in individuals with type II diabetes. This reduction is markedly greater than what would be expected when either component is administered alone, thus indicating a synergistic effect.
- chromic tripicolinate and biotin are commercially available from health food stores, drug stores and other commercial sources.
- this amount is between about 500 and 1,000 ⁇ g/day.
- the preferred daily dosage is between about 25 ⁇ g and 200 mg. More preferably, the daily dosage of biotin is between about 1 mg and 100 mg.
- the chromic picolinates and biotin may be provided as a tablet, aqueous or oil suspension, dispersible powder or granule, emulsion, hard or soft capsule, syrup or elixir.
- Compositions intended for oral use may be prepared according to any method known in the art for the manufacture of pharmaceutically acceptable compositions and such compositions may contain one or more of the following agents: sweeteners, flavoring agents, coloring agents and preservatives. The sweetening and flavoring agents will increase the palatability of the preparation. Tablets containing chromic tripicolinate in admixture with non-toxic pharmaceutically acceptable excipients suitable for tablet manufacture are acceptable.
- compositions should be acceptable in the sense of being compatible with the other ingredients of the formulation (as well as non-injurious to the patient).
- excipients include inert diluents such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, such as corn starch or alginic acid; binding agents such as starch, gelatin or acacia; and lubricating agents such as magnesium stearate, stearic acid or talc. Tablets may be uncoated or may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period of time. For example, a time delay material such as glyceryl monostearate or glyceryl distearate alone or with a wax may be employed.
- Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, such as peanut oil, liquid paraffin or olive oil.
- an inert solid diluent for example calcium carbonate, calcium phosphate or kaolin
- an oil medium such as peanut oil, liquid paraffin or olive oil.
- Aqueous suspensions may contain the chromic tripicolinate complex of the invention in admixture with excipients suitable for the manufacture of aqueous suspensions.
- excipients include suspending agents, dispersing or wetting agents, one or more preservatives, one or more coloring agents, one or more flavoring agents and one or more sweetening agents such as sucrose or saccharin.
- Oil suspensions may be formulated by suspending the active ingredient in a vegetable oil, such as arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin.
- the oil suspension may contain a thickening agent, such as beeswax, hard paraffin or cetyl alcohol.
- Sweetening agents, such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by an added antioxidant such as ascorbic acid.
- Dispersible powders and granules of the invention suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, a suspending agent, and one or more preservatives. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present.
- Syrups and elixirs may be formulated with sweetening agents, such as glycerol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative, a flavoring or a coloring agent.
- sweetening agents such as glycerol, sorbitol or sucrose.
- Such formulations may also contain a demulcent, a preservative, a flavoring or a coloring agent.
- the chromic tripicolinate preparations for parenteral administration may be in the form of a sterile injectable preparation, such as a sterile injectable aqueous or oleaginous suspension.
- a sterile injectable preparation such as a sterile injectable aqueous or oleaginous suspension.
- This suspension may be formulated according to methods well known in the art using suitable dispersing or wetting agents and suspending agents.
- the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, such as a solution in 1,3-butanediol. Suitable diluents include, for example, water, Ringer's solution and isotonic sodium chloride solution.
- sterile fixed oils may be employed conventionally as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono or diglycerides.
- fatty acids such as oleic acid
- the pharmaceutical compositions may also be in the form of oil-in-water emulsions.
- the oily phase may be a vegetable oil, such as olive oil or arachis oil, a mineral oil such as liquid paraffin, or a mixture thereof.
- Suitable emulsifying agents include naturally-occurring gums such as gum acacia and gum tragacanth, naturally occurring phosphatides, such as soybean lecithin, esters or partial esters derived from fatty acids and hexitol anhydrides, such as sorbitan mono-oleate, and condensation products of these partial esters with ethylene oxide, such as polyoxyethylene sorbitan mono-oleate.
- the emulsions may also contain sweetening and flavoring agents.
- chromic tripicolinate/biotin The amount of chromic tripicolinate/biotin that may be combined with the carrier material to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.
Abstract
Description
Claims (26)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/912,472 USRE39480E1 (en) | 1997-08-08 | 2001-07-24 | Chromium/biotin treatment of type II diabetes |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/908,819 US5789401A (en) | 1997-08-08 | 1997-08-08 | High-dose chromium/biotin treatment of type II diabetes |
US09/110,511 US5929066A (en) | 1997-08-08 | 1998-07-06 | Chromium/biotin treatment of Type II diabetes |
US09/912,472 USRE39480E1 (en) | 1997-08-08 | 2001-07-24 | Chromium/biotin treatment of type II diabetes |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/110,511 Reissue US5929066A (en) | 1997-08-08 | 1998-07-06 | Chromium/biotin treatment of Type II diabetes |
Publications (1)
Publication Number | Publication Date |
---|---|
USRE39480E1 true USRE39480E1 (en) | 2007-01-23 |
Family
ID=26808096
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/912,472 Expired - Lifetime USRE39480E1 (en) | 1997-08-08 | 2001-07-24 | Chromium/biotin treatment of type II diabetes |
Country Status (14)
Country | Link |
---|---|
US (1) | USRE39480E1 (en) |
EP (1) | EP1001793B1 (en) |
JP (1) | JP2001513506A (en) |
CN (1) | CN1273531A (en) |
AT (1) | ATE304364T1 (en) |
AU (1) | AU751431B2 (en) |
BR (1) | BR9811137A (en) |
CA (1) | CA2297834C (en) |
CZ (1) | CZ298680B6 (en) |
DE (1) | DE69831576T2 (en) |
ES (1) | ES2251097T3 (en) |
HU (1) | HUP0003713A2 (en) |
IL (1) | IL134163A0 (en) |
WO (1) | WO1999007387A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100009015A1 (en) * | 2007-01-31 | 2010-01-14 | Vijaya Juturu | Use of chromium histidinate for treatment of cardiometabolic disorders |
US8586061B2 (en) | 2007-06-26 | 2013-11-19 | Jds Therapeutics, Llc | Multiple unit dosage form having a therapeutic agent in combination with a nutritional supplement |
US8933022B2 (en) | 2011-03-01 | 2015-01-13 | Jds Therapeutics, Llc | Methods and compositions for the treatment and prevention Hypoglycemia and related disorders |
US9119835B2 (en) | 2007-03-13 | 2015-09-01 | JDS Therapeautics, LLC | Methods and compositions for the sustained release of chromium |
US10820617B1 (en) | 2018-03-29 | 2020-11-03 | Government Of The United States, As Represented By The Secretary Of The Air Force | All inclusive electrolytes, vitamins, and protein powder training supplement |
US11857553B2 (en) | 2016-02-11 | 2024-01-02 | Nutrition21, LLC | Chromium containing compositions for improving health and fitness |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5962030A (en) | 1997-03-07 | 1999-10-05 | Akesis Pharmaceuticals, Inc. | Dietary supplement and method of treatment for diabetic control |
ES2251097T3 (en) | 1997-08-08 | 2006-04-16 | Nutrition 21 | TREATMENT WITH CHROME / BIOTINE OF DIABETES TYPE II. |
CA2344246A1 (en) | 1998-09-17 | 2000-03-23 | Akesis Pharmaceuticals, Inc. | Combinations of chromium or vanadium with antidiabetics for glucose metabolism disorders |
US6376549B1 (en) | 1998-09-17 | 2002-04-23 | Akesis Pharmaceuticals, Inc. | Metforimin-containing compositions for the treatment of diabetes |
PT1397148E (en) * | 2001-02-27 | 2006-11-30 | Nutrition 21 Inc | Chromium/biotin treatment of dyslipidemia |
WO2003090671A2 (en) * | 2002-04-23 | 2003-11-06 | Nutrition 21, Inc. | Chromium compositions and methods for using the same for inhibiting drug-induced insulin resistance |
JP2004043443A (en) * | 2002-05-14 | 2004-02-12 | Kumamoto Technology & Industry Foundation | Preventive and therapeutic medicine of amyloidosis |
WO2003094934A1 (en) * | 2002-05-14 | 2003-11-20 | Nipro Corporation | Medicine for prevention of and treatment for amyloidosis |
JP2004203863A (en) * | 2002-12-09 | 2004-07-22 | Taisho Pharmaceut Co Ltd | Antidiabetic composition |
CN1320925C (en) * | 2005-03-30 | 2007-06-13 | 淮北市辉克药业有限公司 | Long time use compound preparation for treating diabetes |
ES2395529B1 (en) | 2011-06-08 | 2014-04-11 | Pri, S.A. | SYNERGIC COMBINATION FOR THE TREATMENT OF MELLITUS DIABETES TYPE 2. |
CN102488220A (en) * | 2011-11-28 | 2012-06-13 | 中哈福生物医药科技(上海)有限公司 | Hypoglycemic compound, its preparation method and health food with hypoglycemic function |
Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4315927A (en) * | 1980-08-08 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Dietary supplementation with essential metal picolinates |
WO1991011117A2 (en) | 1990-02-05 | 1991-08-08 | Board Of Regents, The University Of Texas System | Dietary supplements comprising vitamins and minerals |
US5087623A (en) * | 1988-05-31 | 1992-02-11 | Nitrition 21 | Chromic picolinate treatment |
US5336672A (en) | 1992-07-21 | 1994-08-09 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Increasing egg production in poultry |
US5470846A (en) | 1994-01-14 | 1995-11-28 | Sandyk; Reuven | Treatment of neurological and mental disorders |
US5496827A (en) | 1994-07-15 | 1996-03-05 | Patrick; Jay | Compositions for the transdermal delivery of nutrients |
WO1996025939A1 (en) | 1995-02-24 | 1996-08-29 | Sabinsa Corporation | Use of piperine as a bioavailability enhancer |
WO1996035421A1 (en) * | 1995-05-12 | 1996-11-14 | Nutrition 21 | High-dose chromic tripicolinate for the treatment of type ii diabetes |
US5597585A (en) | 1995-12-26 | 1997-01-28 | Williams; Andrew H. | Vitamin/mineral composition |
US5635535A (en) | 1996-04-05 | 1997-06-03 | Wagstaff; Robert K. | Method for increasing blood glucose levels |
US5789401A (en) * | 1997-08-08 | 1998-08-04 | Nutrition 21 | High-dose chromium/biotin treatment of type II diabetes |
WO1999007387A1 (en) | 1997-08-08 | 1999-02-18 | Nutrition 21 | Chromium/biotin treatment of type ii diabetes |
US6048846A (en) * | 1998-02-26 | 2000-04-11 | Cochran; Timothy M. | Compositions used in human treatment |
US6140304A (en) | 1988-09-28 | 2000-10-31 | Eicotech Corporation | Method of and nutritional and pharmaceutical compositions for reduction of hyperinsulinemia |
WO2002011564A2 (en) | 2000-08-08 | 2002-02-14 | Advanced Functional Foods International, Inc. | Supplement for type 2 diabetes or lipodystrophy |
-
1998
- 1998-07-31 ES ES98939166T patent/ES2251097T3/en not_active Expired - Lifetime
- 1998-07-31 BR BR9811137-0A patent/BR9811137A/en not_active Application Discontinuation
- 1998-07-31 CN CN98807961A patent/CN1273531A/en active Pending
- 1998-07-31 CA CA002297834A patent/CA2297834C/en not_active Expired - Lifetime
- 1998-07-31 AU AU87651/98A patent/AU751431B2/en not_active Ceased
- 1998-07-31 IL IL13416398A patent/IL134163A0/en active IP Right Grant
- 1998-07-31 AT AT98939166T patent/ATE304364T1/en not_active IP Right Cessation
- 1998-07-31 DE DE69831576T patent/DE69831576T2/en not_active Expired - Lifetime
- 1998-07-31 HU HU0003713A patent/HUP0003713A2/en unknown
- 1998-07-31 JP JP2000506977A patent/JP2001513506A/en active Pending
- 1998-07-31 EP EP98939166A patent/EP1001793B1/en not_active Expired - Lifetime
- 1998-07-31 WO PCT/US1998/016103 patent/WO1999007387A1/en active IP Right Grant
- 1998-07-31 CZ CZ20000324A patent/CZ298680B6/en not_active IP Right Cessation
-
2001
- 2001-07-24 US US09/912,472 patent/USRE39480E1/en not_active Expired - Lifetime
Patent Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4315927A (en) * | 1980-08-08 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Dietary supplementation with essential metal picolinates |
US5087623A (en) * | 1988-05-31 | 1992-02-11 | Nitrition 21 | Chromic picolinate treatment |
US6140304A (en) | 1988-09-28 | 2000-10-31 | Eicotech Corporation | Method of and nutritional and pharmaceutical compositions for reduction of hyperinsulinemia |
WO1991011117A2 (en) | 1990-02-05 | 1991-08-08 | Board Of Regents, The University Of Texas System | Dietary supplements comprising vitamins and minerals |
US5336672A (en) | 1992-07-21 | 1994-08-09 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Increasing egg production in poultry |
US5470846A (en) | 1994-01-14 | 1995-11-28 | Sandyk; Reuven | Treatment of neurological and mental disorders |
US5496827A (en) | 1994-07-15 | 1996-03-05 | Patrick; Jay | Compositions for the transdermal delivery of nutrients |
WO1996025939A1 (en) | 1995-02-24 | 1996-08-29 | Sabinsa Corporation | Use of piperine as a bioavailability enhancer |
WO1996035421A1 (en) * | 1995-05-12 | 1996-11-14 | Nutrition 21 | High-dose chromic tripicolinate for the treatment of type ii diabetes |
US5597585A (en) | 1995-12-26 | 1997-01-28 | Williams; Andrew H. | Vitamin/mineral composition |
US5635535A (en) | 1996-04-05 | 1997-06-03 | Wagstaff; Robert K. | Method for increasing blood glucose levels |
US5789401A (en) * | 1997-08-08 | 1998-08-04 | Nutrition 21 | High-dose chromium/biotin treatment of type II diabetes |
WO1999007387A1 (en) | 1997-08-08 | 1999-02-18 | Nutrition 21 | Chromium/biotin treatment of type ii diabetes |
US6048846A (en) * | 1998-02-26 | 2000-04-11 | Cochran; Timothy M. | Compositions used in human treatment |
WO2002011564A2 (en) | 2000-08-08 | 2002-02-14 | Advanced Functional Foods International, Inc. | Supplement for type 2 diabetes or lipodystrophy |
Non-Patent Citations (14)
Title |
---|
Anderson, R.A. (1997) Nutritional factors influencing the glucose/insulin system: Chromium. Journal of the American College of Nutrition. 16(5):404-410. |
Cefalu et al. (1997) The effect of chromium supplementation on carbohydrate metabolism and body fat distribution. Diabetes. 46:55a. |
Coggeshall, et al. (1985) Biotin status and plasma glucose in diabetics. Ann. N.Y. Acad. Sci. 447:389-392. * |
Copy of label from Multi-Vitamin suppl. "alpha-betic(TM)". * |
Copy of label from Multi-Vitamin suppl. "Mega Men(C)". * |
Maebashi et al. (1993) Therapeutic evaluation of the effect of biotin on hyperglycemia in patients with non-insulin dependent diabetes mellitus. J. Clin. Biochem, Nutr. 14:211-218. |
Maebashi, et al. (1993) Therapeutic evaluation of the effect of biotin on hyperglycemia in patients with non-insulin dependent diabetes mellitus. J. Clin. Biochem. Nutr. 14:211-218. * |
McCarty (1991) The case for supplemental chromium and a survey of clinical studies wiht chromium picolinate. Journal of Applied Nutrition. 43(1):58-66. |
McCarty, Mark F. "Dietary glycemic index may influence cancer risk by modulating IGF-1 activity: a hypothesis." Journal of Medicinal Food. 1(2): 123-140 (1998). |
Mock, D. (1984) In Present Knowledge in Nutrition, 7<SUP>th </SUP>Edition, Chapter 22, pp. 220-235. * |
Ravina et al. (1995) Clinical use of the trace element chromium (III) in the treatment of diabetes mellitus. The Journal of Trace Elements in Experimental Medicine. 8:183-190. |
Reddi, et al. (1988) Biotin supplementation improves glucose and insulin tolerances in genetically diabetic kk mice. Life Sciences. 42:1323-1330. * |
Zhang, et al. (1996) A high biotin improves the impaired glucose tolerance of long-term spontaneously hyperglycemic rats with non-insulin-dependent diabetes mellitus. J. Nutri. Sci. Vitaminol. 42:517-526. * |
Zhang, et al.(1997) Biotin administration improves the impaired glucose tolerance of streptozotocin-induces diabetic Wistar rats. J. Nutri. Sci. Vitaminol. 43(3):271-280. * |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100009015A1 (en) * | 2007-01-31 | 2010-01-14 | Vijaya Juturu | Use of chromium histidinate for treatment of cardiometabolic disorders |
US9119835B2 (en) | 2007-03-13 | 2015-09-01 | JDS Therapeautics, LLC | Methods and compositions for the sustained release of chromium |
US9675702B2 (en) | 2007-03-13 | 2017-06-13 | Jds Therapeutics, Llc | Methods and compositions for the sustained release of chromium |
US9597404B2 (en) | 2007-03-13 | 2017-03-21 | Jds Therapeutics, Llc | Methods and compositions for sustained release of chromium |
US9005637B2 (en) | 2007-06-26 | 2015-04-14 | Jds Therapeutics, Llc | Multiple unit dosage form having a therapeutic agent in combination with a nutritional supplement |
US9421170B2 (en) | 2007-06-26 | 2016-08-23 | Jds Therapeutics, Llc | Multiple unit dosage form having a therapeutic agent in combination with a nutritional supplement |
US8586061B2 (en) | 2007-06-26 | 2013-11-19 | Jds Therapeutics, Llc | Multiple unit dosage form having a therapeutic agent in combination with a nutritional supplement |
US10363222B2 (en) | 2007-06-26 | 2019-07-30 | Jds Therapeutics, Llc | Multiple unit dosage form having a therapeutic agent in combination with a nutritional supplement |
US11241388B2 (en) | 2007-06-26 | 2022-02-08 | Jds Therapeutics, Llc | Multiple unit dosage form having a therapeutic agent in combination with a nutritional supplement |
US11801224B2 (en) | 2007-06-26 | 2023-10-31 | Jds Therapeutics, Llc | Multiple unit dosage form having a therapeutic agent in combination with a nutritional supplement |
US11850308B2 (en) | 2007-06-26 | 2023-12-26 | Bonafide Health, Llc | Multiple unit dosage form having a therapeutic agent in combination with a nutritional supplement |
US8933022B2 (en) | 2011-03-01 | 2015-01-13 | Jds Therapeutics, Llc | Methods and compositions for the treatment and prevention Hypoglycemia and related disorders |
US11857553B2 (en) | 2016-02-11 | 2024-01-02 | Nutrition21, LLC | Chromium containing compositions for improving health and fitness |
US11865121B2 (en) | 2016-02-11 | 2024-01-09 | Nutrition21, LLC | Chromium containing compositions for improving health and fitness |
US10820617B1 (en) | 2018-03-29 | 2020-11-03 | Government Of The United States, As Represented By The Secretary Of The Air Force | All inclusive electrolytes, vitamins, and protein powder training supplement |
Also Published As
Publication number | Publication date |
---|---|
EP1001793B1 (en) | 2005-09-14 |
WO1999007387A1 (en) | 1999-02-18 |
JP2001513506A (en) | 2001-09-04 |
CZ298680B6 (en) | 2007-12-19 |
EP1001793A1 (en) | 2000-05-24 |
CA2297834A1 (en) | 1999-02-18 |
CZ2000324A3 (en) | 2001-03-14 |
CN1273531A (en) | 2000-11-15 |
ES2251097T3 (en) | 2006-04-16 |
IL134163A0 (en) | 2001-04-30 |
BR9811137A (en) | 2000-07-18 |
DE69831576T2 (en) | 2006-06-14 |
AU751431B2 (en) | 2002-08-15 |
ATE304364T1 (en) | 2005-09-15 |
CA2297834C (en) | 2008-09-30 |
HUP0003713A2 (en) | 2001-04-28 |
DE69831576D1 (en) | 2005-10-20 |
AU8765198A (en) | 1999-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5929066A (en) | Chromium/biotin treatment of Type II diabetes | |
USRE39480E1 (en) | Chromium/biotin treatment of type II diabetes | |
EP0825861B1 (en) | High-dose chromic tripicolinate for the treatment of type ii diabetes | |
CA1176981A (en) | Method for preventing body fat deposition in mammals | |
CA1306693C (en) | Pharmaceutical compositions having antineoplastic activity | |
EP1017408B1 (en) | Use of tethrahydrolipstatin in the treatment of diabetes type ii | |
EP0313654B1 (en) | Drug for prophylaxis and treatment of hepatopathy | |
KR20070086007A (en) | Medicinal composition for treating diabetes | |
US20100323031A1 (en) | Synergistic combination to enhance blood glucose and insulin metabolism | |
AU2002302012B2 (en) | Chromim/biotin treatment of type II diabetes | |
EP0137514B1 (en) | Compounds and compositions for use in preventing and treating obesity | |
US5948824A (en) | Use of a chemical agent for reducing the changes in waistline and the effect of constipation due to the taking of other agents | |
MXPA00001214A (en) | Chromium/biotin treatment of type ii diabetes | |
MXPA97008628A (en) | Treatment of type ii diabetes with high doses of picolinato cróm | |
AU704714B2 (en) | Composition for treatment of insulin resistance syndromes | |
KR20050021479A (en) | Use of Ginkgo Biloba Extracts in order to Promote Muscle Mass to the Detriment of Fatty Mass | |
EP0728484A1 (en) | Use of magnesium vanadate for the treatment of insulin resistance syndrome | |
JPH0867637A (en) | Prophylactic and therapeutic agent for hepatopathy | |
WO1996026731A1 (en) | Use of magnesium vanadate for the treatment of insulin resistance syndrome | |
AU4236599A (en) | Compositions for treatment of insulin resistance syndromes | |
JPH0320221A (en) | Hepatopathy therapeutic agent | |
MXPA99007163A (en) | Use of gastrointestinal lipase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FPAY | Fee payment |
Year of fee payment: 12 |
|
AS | Assignment |
Owner name: N21 ACQUISITION HOLDING, LLC, NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NUTRITION 21, LLC;REEL/FRAME:027545/0097 Effective date: 20111122 |
|
AS | Assignment |
Owner name: JDS THERAPEUTICS, LLC, NEW YORK Free format text: CHANGE OF NAME;ASSIGNOR:N21 ACQUISITION HOLDING, LLC;REEL/FRAME:028603/0993 Effective date: 20120201 |
|
AS | Assignment |
Owner name: NUTRITION 21, LLC., NEW YORK Free format text: MERGER;ASSIGNOR:AMBI, INC.;REEL/FRAME:029437/0028 Effective date: 20000101 Owner name: NUTRITION 21 LP, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MCCARTY, MARK F.;REEL/FRAME:029436/0377 Effective date: 19980630 |
|
AS | Assignment |
Owner name: NUTRITION 21, LLC, NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:JDS THERAPEUTICS, LLC;REEL/FRAME:032143/0720 Effective date: 20121203 |
|
AS | Assignment |
Owner name: JDS THERAPEUTICS, LLC, NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NUTRITION 21, LLC;REEL/FRAME:041399/0875 Effective date: 20170221 |
|
AS | Assignment |
Owner name: NUTRITION 21, LLC, NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:JDS THERAPEUTICS, LLC;REEL/FRAME:047666/0467 Effective date: 20181128 |